Royalty Pharma Raises 2026 Portfolio Receipts Guidance Amid Strong Growth
Royalty Pharma (RPRX) has updated its financial outlook, raising its 2026 portfolio receipts guidance to a range of $3.5 billion to $3.55 billion. The company also outlined significant future potential, projecting peak royalties exceeding $1.7 billion. During the Q3 2026 earnings call, CEO Pablo Legorreta reported robust performance characterized by 9% growth in both portfolio and royalty receipts. Key profitability metrics were highlighted, including a return on invested capital (ROIC) of 14.3% and a return on invested equity (ROE) of 20.2%, signaling strong operational efficiency.
Tickers: $RPRX
Topics: earnings report return on invested capital revenue growth royalty receipts